Powered by

Moderna: A Top COVID-19 Vaccine Player, but Is Its Valuation Justified?

Feb 23, 2021 - Nasdaq

Despite the reduction in global Covid-19 cases, and the anticipated gradual return to normalcy, the fear of mutant strains remains.

Jefferies analyst Michael Yee counts the specter of new variants as one of the main reasons why Moderna (MRNA) is well placed to capitalize.

“We strongly believe MRNA is trading on visibility on 2022+ where variant vaccines '2.0' is the focus because the Street fears variants disrupting the recovery, and so long as variants are there, MRNA may benefit ...